https://www.engineeringnews.co.za

Receive our free daily newsletter:

AIDS

AIDS (Acquired Immunodeficiency Syndrome) is the most advanced stage of infection with the human immunodeficiency virus (HIV), characterised by severe damage to the immune system that leaves the body vulnerable to life-threatening opportunistic infections and cancers. The syndrome develops when HIV has destroyed a critical mass of CD4+ T cells, typically defined as a CD4 count below 200 cells per cubic millimetre or the presence of certain defining illnesses. Transmission occurs through contact with infected blood, semen, vaginal fluids or breast milk, most commonly via unprotected sexual intercourse, sharing of needles, mother-to-child transmission during pregnancy or breastfeeding, and contaminated blood transfusions. Without treatment, AIDS typically develops eight to ten years after initial HIV infection, though progression varies widely between individuals. Symptoms include rapid weight loss, recurring fever, profound fatigue, prolonged swelling of lymph glands, chronic diarrhoea, pneumonia, neurological disorders and skin lesions. Sub-Saharan Africa bears the heaviest burden of the epidemic, accounting for approximately two-thirds of all people living with HIV globally, with prevalence rates exceeding 20% of the adult population in some southern African countries. Antiretroviral therapy has transformed AIDS from a near-certain death sentence into a manageable chronic condition, enabling people living with HIV to achieve undetectable viral loads, maintain healthy immune function and live near-normal lifespans. The economic impact of AIDS in high-prevalence countries has been profound, reducing workforce productivity, straining healthcare systems, creating millions of orphans and undermining development gains. Public-health responses combine prevention efforts including condom distribution, voluntary testing and counselling, male circumcision programmes and pre-exposure prophylaxis with expanded access to antiretroviral treatment and care for opportunistic infections. The syndrome was first recognised as a distinct clinical entity in 1981, with HIV identified as the causative agent in 1983, and has since claimed more than 40-million lives worldwide whilst generating unprecedented global health mobilisation and research investment.

AIDS Updates


The Gilead logo displayed on a cellphone
South Africa seeks local production of Gilead's HIV prevention drug
5th March 2026 By: Reuters

South Africa is asking local drugmakers to start a process to make Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, domestically, in a push to bring production to the region where it... 


1

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?

MAGAZINE & ONLINE

SUBSCRIBE

RESEARCH CHANNEL AFRICA

SUBSCRIBE

CORPORATE PACKAGES

CLICK FOR A QUOTATION







301

pqt: 0.042s - ct: 0.1s - 138pq - 2rq
Subscribe Now